Keryx Biopharmaceuticals (KERX)
Keryx Biopharmaceuticals R&D Expense: 7.40M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
KERX R&D Expense Rankings
| Overall | 38th percentile | 1084 of 1763 |
| Sector | 40th percentile | 244 of 413 in Healthcare |
| Industry | 56th percentile | 11 of 25 in Drug Manufacturers - Major |
KERX R&D Expense Range, Past 5 Years
| Minimum | 1.126M | Dec 2008 |
| Maximum | 29.85M | Mar 2008 |
| Average | 7.800M |
About R&D Expense
R&D expenses are a line item from many companies' income statements.
R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.
Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.
An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
Learn More
You may also be interested in these KERX related companies
KERX News
$KERX and i was thinking 2, two weeks ago! I was wrong. counting on u being right
about 9 hours ago by Bleedblue
about 9 hours ago by Bleedblue
$AMRN $kerx $arna $gale bullish on all with FDA Asco such events on the way
about 9 hours ago by newkidontheblock
about 9 hours ago by newkidontheblock
Ceo has over 400k shares conditional upon positive zerenex and fda approval. Thats a big carrot! $kerx is best when volume dry and lonely...
about 9 hours ago by HighRiskBuyer
about 9 hours ago by HighRiskBuyer
RT @gregthor $KERX must have been a helluva presentation this past weekend. Get far wealthier trading other stocks thn $KERX (POS).
about 12 hours ago by JasonMilano8
about 12 hours ago by JasonMilano8
@adamfeuerstein @Gekkowire what do these free shares mean? $kerx
about 13 hours ago by GucciMoccasins
about 13 hours ago by GucciMoccasins
$KERX must have been a helluva presentation this past weekend. Get far wealthier trading other stocks thn $KERX (POS).
about 15 hours ago by gregthor
about 15 hours ago by gregthor
$KERX Stock better run soon ugh money tied up is less money to be had
about 17 hours ago by newkidontheblock
about 17 hours ago by newkidontheblock
$AMRN will buy at $10.55, $KERX will buy at $1.66, $SPPI will buy at $10.75
about 17 hours ago by JasonMilano8
about 17 hours ago by JasonMilano8
RT @traderstewie $KERX Why is this quote feed 15 minutes old? WTF is going on with quotes today? SO delayed.
about 18 hours ago by SomeGuy900
about 18 hours ago by SomeGuy900
$KERX Why is this quote feed 15 minutes old? WTF is going on with quotes today? SO delayed.
about 19 hours ago by SomeGuy900
about 19 hours ago by SomeGuy900
$KERX Reading rumors about secondary offering. Do you think it could happen? This stock is like playing craps in Vegas.
about 20 hours ago by Scott_biotech
about 20 hours ago by Scott_biotech
$kerx nevermind, i see it now. Looking for 2 today and more the next couple of days.
about a day ago by HighRiskBuyer
about a day ago by HighRiskBuyer
M&A Activity and Growing Rate of FDA Approvals Contributing Factors to Biotech Industry's Recent Boom
May 21, 8:20AM Marketwire
May 21, 8:20AM Marketwire
BMC Software, The Ultimate Software Group Included in Stocks Up on High Volume Monday
May 14, 12:33PM Fox Business
May 14, 12:33PM Fox Business
Morning Movers 05/14: (GOLF) (VTUS) (KERX) Higher; (IOC) (ACOM) (ANIK) Lower
May 14, 10:07AM Street Insider
May 14, 10:07AM Street Insider
Unusual 11 Mid-Day Movers 05/10: (ADY) (INSP) (RPRX) Higher; (SGI) (WFR) (ARX) Lower
May 10, 2:24PM Street Insider
May 10, 2:24PM Street Insider
UPDATE: Ladenburg Thalmann Upgrades Keryx Biopharmaceuticals; Establishes PT
May 10, 10:54AM Benzinga
May 10, 10:54AM Benzinga
Keryx Biopharmaceuticals to Present at The 11th Annual JMP Securities Research Conference
May 10, 8:30AM PR Newswire
May 10, 8:30AM PR Newswire
Aeterna (AEZS), Keryx (KERX) Terminate Perifosine License Agreement in North America
May 07, 7:40AM Street Insider
May 07, 7:40AM Street Insider
Pharmaceutical Companies Look to Biotech Industry to Combat Losses From Expiring Patents
Apr 23, 8:20AM Marketwire
Apr 23, 8:20AM Marketwire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| KERX | 1.70 | -0.05 | -2.86% | 120.73M |
| KALU | 50.67 | +1.21 | +2.45% | 975.40M |
| K | 50.48 | +0.21 | +0.42% | 18.03B |
| JYF | 32.24 | -0.09 | -0.28% | |
| JXSB | 17.76 | +0.42 | +2.40% | 34.09M |
| JXI | 40.61 | -0.21 | -0.51% | |
| JWN | 51.08 | +0.34 | +0.67% | 10.62B |
| JVA | 7.89 | +0.30 | +3.95% | 50.26M |
| JTP | 8.26 | -0.01 | -0.12% | |
| JST | 7.25 | -0.35 | -4.61% | 118.90M |
